{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:50Z","timestamp":1780791170625,"version":"3.54.1"},"reference-count":53,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin\/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS).\r\nPatients and methods: The retrospective study was conducted between May 2022 and February 2023. Fifty-eight female FS patients (mean age: 45.2\u00b19.9 years; range, 25 to 66 years) and 30 age- and body mass index-matched control subjects (mean age: 43.1\u00b19.9 years; range, 26 to 67 years) were included in the study. Apelin and PCSK9 levels of all individuals were measured using appropriate methods.\r\nResults: The levels of PCSK9 (173.2\u00b162.2 vs. 75.1\u00b144.1, p<\/jats:p>","DOI":"10.46497\/archrheumatol.2024.10462","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:33:43Z","timestamp":1724830423000},"page":"375-383","source":"Crossref","is-referenced-by-count":3,"title":["Proprotein convertase subtilisin\/kexin type 9 and apelin in fibromyalgia syndrome"],"prefix":"10.5152","volume":"39","author":[{"family":"Nevsun Pihtili Ta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rabia Aydogan Baykara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ayhan Kamanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ali G\u00fcrb\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Erkan Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Medine Cumhur C\u00fcre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mehmet Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tugce Tasar Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: Literature review update. Rev Bras Reumatol Engl Ed 2017;57:356-63. doi: 10.1016\/j.rbre.2017.01.005.","DOI":"10.1016\/j.rbre.2017.01.005"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Galvez-S\u00e1nchez CM, Duschek S, Reyes Del Paso GA. Psychological impact of fibromyalgia: Current perspectives. Psychol Res Behav Manag 2019;12:117- 27. doi: 10.2147\/PRBM.S178240.","DOI":"10.2147\/PRBM.S178240"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Yunus MB. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat 2012;2012:584573. doi: 10.1155\/2012\/584573.","DOI":"10.1155\/2012\/584573"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:426130. doi: 10.1155\/2012\/426130.","DOI":"10.1155\/2012\/426130"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Yao WC, Chen HJ, Leong KH, Chang KL, Wang YT, Wu LC, et al. The risk of fibromyalgia in patients with iron deficiency anemia: A nationwide populationbased cohort study. Sci Rep 2021;11:10496. doi: 10.1038\/s41598-021-89842-9.","DOI":"10.1038\/s41598-021-89842-9"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Assavarittirong C, Samborski W, GrygielG\u00f3rniak B. Oxidative stress in fibromyalgia: From pathology to treatment. Oxid Med Cell Longev 2022;2022:1582432. doi: 10.1155\/2022\/1582432.","DOI":"10.1155\/2022\/1582432"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Tel Ad\u0131g\u00fczel K, K\u00f6ro\u00a4lu \u00d6, Ya\u015far E, Tan AK, Samur G. The relationship between dietary total antioxidant capacity, clinical parameters, and oxidative stress in fibromyalgia syndrome: A novel point of view. Turk J Phys Med Rehabil 2022;68:262-70. doi: 10.5606\/ tftrd.2022.9741.","DOI":"10.5606\/tftrd.2022.9741"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: Etiologic and therapeutic concerns. Rheumatol Int 2006;26:598- 603. doi: 10.1007\/s00296-005-0079-y.","DOI":"10.1007\/s00296-005-0079-y"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: A controlled study. Rheumatol Int 2009;29:629-33. doi: 10.1007\/s00296-008-0738-x.","DOI":"10.1007\/s00296-008-0738-x"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008;105:13045-50. doi: 10.1073\/pnas.0806312105.","DOI":"10.1073\/pnas.0806312105"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem Sci 2007;32:71-7. doi: 10.1016\/j.tibs.2006.12.008.","DOI":"10.1016\/j.tibs.2006.12.008"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, et al. Overview of OxLDL and its impact on cardiovascular health: Focus on atherosclerosis. Front Pharmacol 2021;11:613780. doi: 10.3389\/ fphar.2020.613780.","DOI":"10.3389\/fphar.2020.613780"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Luquero A, Badimon L, Borrell-Pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front Cardiovasc Med 2021;8:639727. doi: 10.3389\/fcvm.2021.639727.","DOI":"10.3389\/fcvm.2021.639727"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Palmer ES, Irwin N, O'Harte FP. Potential therapeutic role for apelin and related peptides in diabetes: An update. Clin Med Insights Endocrinol Diabetes 2022;15:11795514221074679. doi: 10.1177\/11795514221074679.","DOI":"10.1177\/11795514221074679"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, et al. The role of Apelin-APJ system in diabetes and obesity. Front Endocrinol (Lausanne) 2022;13:820002. doi: 10.3389\/fendo.2022.820002.","DOI":"10.3389\/fendo.2022.820002"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The role of apelin in cardiovascular diseases, obesity and cancer. Front Physiol 2018;9:557. doi: 10.3389\/ fphys.2018.00557.","DOI":"10.3389\/fphys.2018.00557"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Lu L, Wu D, Li L, Chen L. Apelin\/APJ system: A bifunctional target for cardiac hypertrophy. Int J Cardiol 2017;230:164-70. doi: 10.1016\/j. ijcard.2016.11.215.","DOI":"10.1016\/j.ijcard.2016.11.215"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10. doi: 10.1002\/acr.20140.","DOI":"10.1002\/acr.20140"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Yanmaz MN, Atar S, Bi\u00e7er M. The reliability and validity of the Turkish version of fibromyalgia survey diagnostic criteria and symptom severity scale. J Back Musculoskelet Rehabil 2016;29:287-93. doi: 10.3233\/BMR-150627.","DOI":"10.3233\/BMR-150627"},{"key":"ref-20","unstructured":"Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18:728-33."},{"key":"ref-21","unstructured":"Ulusoy M, Nesrin HS, Erkmen H. Turkish Version of the Beck Anxiety Inventory: Psychometric Properties. J Cogn Psychother 1998;12:2."},{"key":"ref-22","unstructured":"Hisli N. Validity and Reliability of Beck Depression Inventory for University Students. J Psychol 1989;7:3- 13."},{"key":"ref-23","unstructured":"Yaray O, Akesen B, Ocaklio\u00a4lu G, Aydinli U. Validation of the Turkish version of the visual analog scale spine score in patients with spinal fractures. Acta Orthop Traumatol Turc 2011;45:353-8. doi: 10.3944\/AOTT.2011.2528."},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213. doi: 10.1016\/0165- 1781(89)90047-4.","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Larson AA, Pardo JV, Pasley JD. Review of overlap between thermoregulation and pain modulation in fibromyalgia. Clin J Pain 2014;30:544-55. doi: 10.1097\/AJP.0b013e3182a0e383.","DOI":"10.1097\/AJP.0b013e3182a0e383"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986;15:165-73. doi: 10.3109\/03009748609102084.","DOI":"10.3109\/03009748609102084"},{"key":"ref-27","unstructured":"Fatima G, Das SK, Mahdi AA. Oxidative stress and antioxidative parameters and metal ion content in patients with fibromyalgia syndrome: Implications in the pathogenesis of the disease. Clin Exp Rheumatol 2013;31(6 Suppl 79):S128-33."},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Schwartz ES, Lee I, Chung K, Mo Chung J. Oxidative stress in the spinal cord is an important contributor in capsaicin-induced mechanical secondary hyperalgesia in mice. Pain 2008;138:514-24. doi: 10.1016\/j. pain.2008.01.029.","DOI":"10.1016\/j.pain.2008.01.029"},{"key":"ref-29","doi-asserted-by":"crossref","unstructured":"Kutu FC, \u00d6zdolap \u015e, Sarikaya S. Proinflammatory cytokines and oxidized low-densitylipoprotein in patients with fibromyalgia. Arch Rheumatol 2018;34:123-29. doi: 10.5606\/ ArchRheumatol.2019.6733.","DOI":"10.5606\/ArchRheumatol.2019.6733"},{"key":"ref-30","doi-asserted-by":"crossref","unstructured":"\u00c7etinkaya FN, Ko\u00e7ak FA, Kurt EE, G\u00fc\u00e7l\u00fc K, Tuncay F, \u015ea\u015f S, et al. The effects of balneotherapy on oxidant\/ antioxidant status in patients with fibromyalgia: An observational study. Arch Rheumatol 2020;35:506- 14. doi: 10.46497\/ArchRheumatol.2020.7857.","DOI":"10.46497\/ArchRheumatol.2020.7857"},{"key":"ref-31","doi-asserted-by":"crossref","unstructured":"Ozgocmen S, Ardicoglu O. Lipid profile in patients with fibromyalgia and myofascial pain syndromes. Yonsei Med J 2000;41:541-5. doi: 10.3349\/ ymj.2000.41.5.541.","DOI":"10.3349\/ymj.2000.41.5.541"},{"key":"ref-32","unstructured":"Yildirim T, Alp R. The role of oxidative stress in the relation between fibromyalgia and obstructive sleep apnea syndrome. Eur Rev Med Pharmacol Sci 2017;21:20-9."},{"key":"ref-33","doi-asserted-by":"crossref","unstructured":"Cammisotto V, Baratta F, Simeone PG, Barale C, Lupia E, Galardo G, et al. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) beyond lipids: The role in oxidative stress and thrombosis. Antioxidants (Basel) 2022;11:569. doi: 10.3390\/ antiox11030569.","DOI":"10.3390\/antiox11030569"},{"key":"ref-34","doi-asserted-by":"crossref","unstructured":"Safaeian L, Mirian M, Bahrizadeh S. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2 -induced oxidative stress. Arch Physiol Biochem [Internet] 2022;128:1681-6.","DOI":"10.1080\/13813455.2020.1788605"},{"key":"ref-35","doi-asserted-by":"crossref","unstructured":"Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: Markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010;125:287-94. doi: 10.1016\/j.jad.2009.12.014.","DOI":"10.1016\/j.jad.2009.12.014"},{"key":"ref-36","doi-asserted-by":"crossref","unstructured":"Lohoff FW. Lipid-lowering drug effects beyond the cardiovascular system: Relevance for neuropsychiatric disorders. Int J Neuropsychopharmacol 2018;21:1076- 78. doi: 10.1093\/ijnp\/pyy087.","DOI":"10.1093\/ijnp\/pyy087"},{"key":"ref-37","doi-asserted-by":"crossref","unstructured":"Macchi C, Favero C, Ceresa A, Vigna L, Conti DM, Pesatori AC, et al. Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovasc Diabetol 2020;19:187. doi: 10.1186\/s12933-020- 01158-6.","DOI":"10.1186\/s12933-020-01158-6"},{"key":"ref-38","doi-asserted-by":"crossref","unstructured":"Cordero MD, Alcocer-G\u00f3mez E, Cano-Garc\u00eda FJ, S\u00e1nchez-Dom\u00ednguez B, Fern\u00e1ndez-Riejo P, Moreno Fern\u00e1ndez AM, et al. Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. Rheumatol Int 2014;34:419-22. doi: 10.1007\/ s00296-012-2647-2.","DOI":"10.1007\/s00296-012-2647-2"},{"key":"ref-39","doi-asserted-by":"crossref","unstructured":"Fang C, Luo T, Lin L. Elevation of serum Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus. Ann Transl Med 2018;6:452. doi: 10.21037\/atm.2018.11.04.","DOI":"10.21037\/atm.2018.11.04"},{"key":"ref-40","doi-asserted-by":"crossref","unstructured":"Andra CA, Rambe AS, Hasan R, Sembiring R, Firman D, Eyanoer PC, et al. Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) as a marker of coronary lesion severity in stable Coronary Artery Disease (CAD) patients. Narra J 2023;3:e409. doi: 10.52225\/narra.v3i3.409.","DOI":"10.52225\/narra.v3i3.409"},{"key":"ref-41","doi-asserted-by":"crossref","unstructured":"Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6. doi: 10.1006\/bbrc.1998.9489.","DOI":"10.1006\/bbrc.1998.9489"},{"key":"ref-42","doi-asserted-by":"crossref","unstructured":"Shin K, Pandey A, Liu XQ, Anini Y, Rainey JK. Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio 2013;3:328-33. doi: 10.1016\/j.fob.2013.08.001.","DOI":"10.1016\/j.fob.2013.08.001"},{"key":"ref-43","doi-asserted-by":"crossref","unstructured":"Wang W, Shen M, Fischer C, Basu R, Hazra S, Couvineau P, et al. Apelin protects against abdominal  aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proc Natl Acad Sci U S A 2019;116:13006-15. doi: 10.1073\/ pnas.1900152116.","DOI":"10.1073\/pnas.1900152116"},{"key":"ref-44","doi-asserted-by":"crossref","unstructured":"Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007;115:428-32. doi: 10.1055\/s-2007- 971067.","DOI":"10.1055\/s-2007-971067"},{"key":"ref-45","doi-asserted-by":"crossref","unstructured":"Lv D, Li H, Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2013;45:527-33. doi: 10.1093\/abbs\/gmt040.","DOI":"10.1093\/abbs\/gmt040"},{"key":"ref-46","doi-asserted-by":"crossref","unstructured":"Zhou Q, Cao J, Chen L. Apelin\/APJ system: A novel therapeutic target for oxidative stress-related inflammatory diseases (Review). Int J Mol Med 2016;37:1159-69. doi: 10.3892\/ijmm.2016.2544.","DOI":"10.3892\/ijmm.2016.2544"},{"key":"ref-47","doi-asserted-by":"crossref","unstructured":"El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR. Apelin: A potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010;70:421-7. doi: 10.3109\/00365513.2010.504281.","DOI":"10.3109\/00365513.2010.504281"},{"key":"ref-48","doi-asserted-by":"crossref","unstructured":"Ferdinal F, Limanan D, Rini RD, Alexsandro R, Helmi R. Elevated levels of Apelin-36 in heart failure due to chronic systemic hypoxia. Int J Angiol 2019;28:194- 99. doi: 10.1055\/s-0038-1676340.","DOI":"10.1055\/s-0038-1676340"},{"key":"ref-49","doi-asserted-by":"crossref","unstructured":"Hajimashhadi Z, Aboutaleb N, Nasirinezhad F. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides 2017;61:15-22. doi: 10.1016\/j. npep.2016.08.010.","DOI":"10.1016\/j.npep.2016.08.010"},{"key":"ref-50","doi-asserted-by":"crossref","unstructured":"Lv SY, Qin YJ, Wang NB, Yang YJ, Chen Q. Supraspinal antinociceptive effect of apelin-13 in a mouse visceral pain model. Peptides 2012;37:165-70. doi: 10.1016\/j.peptides.2012.06.007.","DOI":"10.1016\/j.peptides.2012.06.007"},{"key":"ref-51","doi-asserted-by":"crossref","unstructured":"Dai L, Smith PM, Kuksis M, Ferguson AV. Apelin acts in the subfornical organ to influence neuronal excitability and cardiovascular function. J Physiol 2013;591:3421- 32. doi: 10.1113\/jphysiol.2013.254144.","DOI":"10.1113\/jphysiol.2013.254144"},{"key":"ref-52","doi-asserted-by":"crossref","unstructured":"Canpolat S, Ozcan M, Saral S, Kalkan OF, Ayar A. Effects of apelin-13 in mice model of experimental pain and peripheral nociceptive signaling in rat sensory neurons. J Recept Signal Transduct Res 2016;36:243- 7. doi: 10.3109\/10799893.2015.1080274.","DOI":"10.3109\/10799893.2015.1080274"},{"key":"ref-53","doi-asserted-by":"crossref","unstructured":"Gok Oguz E, Akoglu H, Ulusal Okyay G, Yayar O, Karaveli Gursoy G, Buyukbakkal M, et al. Serum apelin is associated with affective disorders in peritoneal dialysis patients. Ren Fail 2016;38:1059- 66. doi: 10.1080\/0886022X.2016.1193873.","DOI":"10.1080\/0886022X.2016.1193873"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1427\/2546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1427\/2547","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1427\/2546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:01:09Z","timestamp":1761210069000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,30]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2024.10462","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}